Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Marina Elena Cazzaniga; Paolo Pronzato; Domenico Amoroso; Antonio Bernardo; Laura Biganzoli; Giancarlo Bisagni; Livio Blasi; Emilio Bria; Francesco Cognetti; Lucio Crinò; Michelino De Laurentiis; Lucia Del Mastro; Sabino De Placido; Alessandra Beano; Francesco Ferraù; Silva Foladore; Rosachiara Forcignanò; Teresa Gamucci; Ornella Garrone; Alessandra Gennari; Monica Giordano; Francesco Giotta; Filippo Giovanardi; Luciano Latini; Lorenzo Livi; Paolo Marchetti; Rodolfo Mattioli; Andrea Michelotti; Filippo Montemurro; Carlo Putzu; Ferdinando Riccardi; Giuseppina Ricciardi; Emanuela Romagnoli; Giuseppina Sarobba; Simon Spazzapan; Pierosandro Tagliaferri; Nicola Tinari; Giuseppe Tonini; Anna Turletti; Claudio Verusio; Alberto Zambelli; Giorgio Mustacchi

doi:10.3390/cancers16010117

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Marina Elena Cazzaniga
, Paolo Pronzato
, Domenico Amoroso
, Antonio Bernardo
, Laura Biganzoli
, Giancarlo Bisagni
, Livio Blasi
, Emilio Bria
, Francesco Cognetti
, Lucio Crinò
, Michelino De Laurentiis
, Lucia Del Mastro
, Sabino De Placido
, Alessandra Beano
, Francesco Ferraù
, Silva Foladore
, Rosachiara Forcignanò
, Teresa Gamucci
, Ornella Garrone
, Alessandra Gennari

Monica Giordano, Francesco Giotta, Filippo Giovanardi, Luciano Latini, Lorenzo Livi, Paolo Marchetti, Rodolfo Mattioli, Andrea Michelotti, Filippo Montemurro, Carlo Putzu, Ferdinando Riccardi, Giuseppina Ricciardi, Emanuela Romagnoli, Giuseppina Sarobba, Simon Spazzapan, Pierosandro Tagliaferri, Nicola Tinari, Giuseppe Tonini, Anna Turletti, Claudio Verusio, Alberto Zambelli, Giorgio Mustacchi

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.

Original language	English
Article number	117
Journal	Cancers
Volume	16
Issue number	1
DOIs	https://doi.org/10.3390/cancers16010117
Publication status	Published - Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

HER2 negative
metastatic breast cancer
overall survival
progression free survival
time to treatment change

Access to Document

10.3390/cancers16010117

Cite this

Cazzaniga, M. E., Pronzato, P., Amoroso, D., Bernardo, A., Biganzoli, L., Bisagni, G., Blasi, L., Bria, E., Cognetti, F., Crinò, L., De Laurentiis, M., Del Mastro, L., De Placido, S., Beano, A., Ferraù, F., Foladore, S., Forcignanò, R., Gamucci, T., Garrone, O., ... Mustacchi, G. (2024). Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study. Cancers, 16(1), Article 117. https://doi.org/10.3390/cancers16010117

@article{ae4c87639a2742ff8987183a2f66edae,

title = "Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study",

abstract = "GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes{\textendash}based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2\%) and TNBC (33.3\%) patients. The median PFS1 was 12.5 months (95\% CI 16.79{\textendash}19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months{\textemdash}95\% CI 5.7{\textendash}9.2) in comparison to Luminal A (13.2 months, 95\% CI 11.7{\textendash}15.1) and Luminal B patients (11.8 months, 95\% CI 10.3{\textendash}12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95\% CI 4.3{\textendash}6.5 vs. Luminal A{\textemdash}9.4, 95\% CI 8.1{\textendash}10.7, and Luminal B{\textemdash}7.7 95\% CI 6.8{\textendash}8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95\% CI 30.8{\textendash}37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95\% CI 26.2{\textendash}31.2) and TNBC (18.5 months, 95\% CI 16{\textendash}20.1, F-ratio 7.44, p = 0.0006). The GIM 13{\textemdash}AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.",

keywords = "HER2 negative, metastatic breast cancer, overall survival, progression free survival, time to treatment change",

author = "Cazzaniga, \{Marina Elena\} and Paolo Pronzato and Domenico Amoroso and Antonio Bernardo and Laura Biganzoli and Giancarlo Bisagni and Livio Blasi and Emilio Bria and Francesco Cognetti and Lucio Crin{\`o} and \{De Laurentiis\}, Michelino and \{Del Mastro\}, Lucia and \{De Placido\}, Sabino and Alessandra Beano and Francesco Ferra{\`u} and Silva Foladore and Rosachiara Forcignan{\`o} and Teresa Gamucci and Ornella Garrone and Alessandra Gennari and Monica Giordano and Francesco Giotta and Filippo Giovanardi and Luciano Latini and Lorenzo Livi and Paolo Marchetti and Rodolfo Mattioli and Andrea Michelotti and Filippo Montemurro and Carlo Putzu and Ferdinando Riccardi and Giuseppina Ricciardi and Emanuela Romagnoli and Giuseppina Sarobba and Simon Spazzapan and Pierosandro Tagliaferri and Nicola Tinari and Giuseppe Tonini and Anna Turletti and Claudio Verusio and Alberto Zambelli and Giorgio Mustacchi",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2024",

month = jan,

doi = "10.3390/cancers16010117",

language = "English",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

Cazzaniga, ME, Pronzato, P, Amoroso, D, Bernardo, A, Biganzoli, L, Bisagni, G, Blasi, L, Bria, E, Cognetti, F, Crinò, L, De Laurentiis, M, Del Mastro, L, De Placido, S, Beano, A, Ferraù, F, Foladore, S, Forcignanò, R, Gamucci, T, Garrone, O, Gennari, A, Giordano, M, Giotta, F, Giovanardi, F, Latini, L, Livi, L, Marchetti, P, Mattioli, R, Michelotti, A, Montemurro, F, Putzu, C, Riccardi, F, Ricciardi, G, Romagnoli, E, Sarobba, G, Spazzapan, S, Tagliaferri, P, Tinari, N, Tonini, G, Turletti, A, Verusio, C, Zambelli, A & Mustacchi, G 2024, 'Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study', Cancers, vol. 16, no. 1, 117. https://doi.org/10.3390/cancers16010117

TY - JOUR

T1 - Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade

T2 - Results of the GIM 13-AMBRA Study

AU - Cazzaniga, Marina Elena

AU - Pronzato, Paolo

AU - Amoroso, Domenico

AU - Bernardo, Antonio

AU - Biganzoli, Laura

AU - Bisagni, Giancarlo

AU - Blasi, Livio

AU - Bria, Emilio

AU - Cognetti, Francesco

AU - Crinò, Lucio

AU - De Laurentiis, Michelino

AU - Del Mastro, Lucia

AU - De Placido, Sabino

AU - Beano, Alessandra

AU - Ferraù, Francesco

AU - Foladore, Silva

AU - Forcignanò, Rosachiara

AU - Gamucci, Teresa

AU - Garrone, Ornella

AU - Gennari, Alessandra

AU - Giordano, Monica

AU - Giotta, Francesco

AU - Giovanardi, Filippo

AU - Latini, Luciano

AU - Livi, Lorenzo

AU - Marchetti, Paolo

AU - Mattioli, Rodolfo

AU - Michelotti, Andrea

AU - Montemurro, Filippo

AU - Putzu, Carlo

AU - Riccardi, Ferdinando

AU - Ricciardi, Giuseppina

AU - Romagnoli, Emanuela

AU - Sarobba, Giuseppina

AU - Spazzapan, Simon

AU - Tagliaferri, Pierosandro

AU - Tinari, Nicola

AU - Tonini, Giuseppe

AU - Turletti, Anna

AU - Verusio, Claudio

AU - Zambelli, Alberto

AU - Mustacchi, Giorgio

PY - 2024/1

Y1 - 2024/1

N2 - GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.

AB - GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.

KW - HER2 negative

KW - metastatic breast cancer

KW - overall survival

KW - progression free survival

KW - time to treatment change

UR - https://www.scopus.com/pages/publications/85182207108

U2 - 10.3390/cancers16010117

DO - 10.3390/cancers16010117

M3 - Article

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 1

M1 - 117

ER -

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this